AstraZeneca Reaffirms Safety Of Covishield Vaxzevria Vaccines Amid Blood Clot Concerns

In light of recent concerns surrounding potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant has reiterated its commitment to patient safety while emphasising the vaccine's overall safety profile. This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome (TTS). Despite these rare occurrences, the pharmaceutical company maintains that extensive clinical trial data and real-world evidence consistently support the vaccine's safety and efficacy.